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atic literature review (May, 2015) to identify clinical trial evidence (i.e. randomized 
controlled trials, non-randomized controlled trials, and single-arm clinical trials) 
assessing sustained virological response rates among interferon-free and inter-
feron-containing antiviral regimens for hepatitis C. NMA require that the network 
is connected in order to facilitate adjusted indirect comparisons by which the 
treatment effect is isolated from the study effect. The study effects are estimated 
using common comparators. In the absence of common comparators, we incorpo-
rated the single-arm data directly into the Bayesian framework using simulated 
controls. The simulated controls were obtained by first modeling the reference 
treatment, and then using the constructed model to predict the most likely con-
trol outcome values given the observed trial characteristics. Using the simulated 
controls, traditional NMA methods were applied to the resulting data. Results: 
Seventy clinical trial arms, including 8,997 patients, contributed to the analysis of 
sustained virological response (SVR). All interferon-free regimens were statistically 
advantageous when compared to peginterferon-ribavirin (RR> 2.00). Furthermore, 
all interferon-free regimens were statistically better than telaprevir+peginterferon-
ribavirin, boceprevir+peginterferon-ribavirin, simeprevir+peginterferon-ribavirin, 
and sofosbuvir+ribavirin (RR> 1.25). No statistical differences were observed 
between the interferon-free regimens. Given the large disparity between the two 
treatment classes, use of simulated-control NMA did not lead to large differences 
in conclusions when compared to the naïve approach; however, the magnitude of 
estimates and rankings were affected. ConClusions: The use of single-arm tri-
als to assess interferon-free antivirals is common. We have shown that advanced 
statistical modeling can be used to assess the comparative efficacy new interferon-
free antiviral regimens.
PIN5
DaclatasvIr +asuNaPrevIr versus sofosbuvIr/leDIPasvIr for the 
treatmeNt of chroNIc hePatItIs c GeNotyPe 1 IN JaPaNese PatIeNts: a 
matchING-aDJusteD INDIrect comParIsoN
Swallow E1, Kelley C1, Ristovska L1, Signorovitch JE1, Kalsekar A2, Wygant G2, McPhee F2
1Analysis Group, Inc., Boston, MA, USA, 2Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, 
NJ, USA
objeCtives: To compare daclatasvir and asunaprevir (DCV+ASV) versus sofosbuvir/
ledipasvir (SOF/LDV) for HCV genotype 1b in Japanese patients without nonstruc-
tural protein 5A (NS5A) polymorphisms. Methods: Individual patient data were 
available from the two Phase 3 trials of DCV+ASV conducted in Japan (BMS 026/031); 
published summary data were extracted from the one Phase 3 trial of SOF/LDV con-
ducted in Japan (Mizokami et al.). Patients treated with DCV+ASV without baseline 
NS5A polymorphisms at L31F/I/M/V or Y93H were included in the present analysis 
and were subject to the enrollment criteria reported in the SOF/LDV trial. To adjust 
for cross-trial differences, patients in the DCV+ASV trial were weighted to match 
reported summary baseline characteristics: age, BMI, gender, prior treatment experi-
ence, prior treatment response, interferon eligibility, HCV RNA level, IL28B genotype, 
cirrhosis status, alanine aminotransferase, albumin, and platelets. Sustained viro-
logic response at week 12 post-treatment (SVR12) and discontinuation due to adverse 
events (AEs) were compared between the treatments. Results: Of the 363 patients 
treated with DCV+ASV, 282 had no baseline NS5A polymorphisms. Of these, 252 met 
the inclusion criteria of the SOF/LDV trial (n= 171) and were included in the analy-
sis. Prior to adjustment, the rate of SVR12 was lower among patients treated with 
DCV+ASV than SOF/LDV (95.2% vs. 100%; p= 0.004) and the rate of discontinuation 
due to AEs was higher among patients treated with DCV+ASV than SOF/LDV 
(4.8% vs. 0.0%; p= 0.004). After adjustment, both the rate of SVR12 and discontinu-
ation due to AEs were similar between patients treated with DCV+ASV and SOF/
LDV (SVR12: 99.3% vs. 100%; p= 0.398; discontinuation due to AEs: 1.3% vs. 0.0%; 
p= 0.327). ConClusions: After adjustment for cross-trial differences in baseline 
characteristics, DCV+ASV and SOF/LDV were associated with similar efficacy and 
discontinuation due to AEs in the treatment of HCV genotype 1b in Japanese patients 
without NS5A polymorphisms at L31F/I/M/V or Y93H.
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objeCtives: Several randomized control clinical trials have shown that Probiotics 
lower the death rates of preterm newborns with necrotising enterocolitis. However, 
most clinical guidelines do not currently support use of Probiotics. The objective 
of this study was to conduct a meta-analysis of mortality data from all available 
randomized control trials for Probiotics. Methods: A systematic literature search 
for randomized clinical trials for use of Probiotics in preterm newborns with necro-
tising enterocolitis (NEC) was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar and Cochrane. Data was collected for the study type, methods, coun-
try and key findings. Extracted study data included study design, patient charat-
certristcis and NEC related outcomes. A random effects meta-analysis model was 
developed to estimate overall odds ratios and risk ratio. A bayesian random effects 
network meta-analysis model with vague and informative priors was also devel-
oped. Results: We identified 350 references and found 23 randomized trials in 7136 
newborns with 408 events. The mean size of the clinical trials was approximately 
300 patients. In the Probiotics and Placebo groups, there were 166 and 242 deaths, 
respectively. The random effects Odds Ratio for mortality for Probiotics versus 
Placebo was 0.69 (95% confidence interval 0.56 and 0.86; P= 0.0007). The random 
effects risk ratio for mortality for Probiotics versus Placebo was 0.72 (95% confidence 
interval 0.60 and 0.88; P= 0.00010). ConClusions: This large meta-analysis shows 
that use of Probiotics significantly reduces the risk and odds of death in preterm 
newborns with necrotising enterocolitis. There is an urgent need for updating clini-
cal guidelines based on this cumulative evidence.
general population controls. Results: In total, 49 026 patients with a HCV diag-
nosis were identified, of which 34 633 CHC patients were still alive and in Sweden 
on December 31st 2013 resulting in a CHC prevalence of 0.36% in 2013 (in males: 
0.46%; in females: 0.26%). Mean age in 2013 was 49 years (SD 12.95). Chronic liver 
disease and complications or symptoms of liver disease (including varices, ascites, 
liver cirrhosis, liver cancer and liver transplantation) were diagnosed and regis-
tered in 11% of CHC patients. Overall, 14.4% of all CHC patients had a co-infection 
with hepatitis B or HIV compared with 0.3% in the matched general population 
controls. The prevalence of psychiatric disorder, vascular, circulatory, and meta-
bolic disease were significantly higher in CHC patients compared with the general 
population controls. ConClusions: Our CHC prevalence was lower than previously 
reported. Patients with CHC had notably increased risk of other diseases compared 
to matched general population controls.
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objeCtives: To provide real-world evidence from a Japanese healthcare database 
on the status of MRSA infections and the usage of anti-MRSA drugs in actual 
clinical settings. The overall medical treatment of MRSA patients was also inves-
tigated. Methods: This was a retrospective study based on claims data from 
a Japanese healthcare database composed of annual health check and claims 
from approximately 2.3 million members of employment-based health insurance 
groups and their dependents. The data of patients who had at least one record of 
being diagnosed with an MRSA infection (U80.1 in ICD-10/v2010) and being pre-
scribed anti-MRSA drugs approved in Japan were extracted from the 2014 database. 
An adult patient was defined as 15 years of age or older. Results: We identified 
patients (35.6% female, 77.7% adult) with an infection episode matching our defi-
nition. Among the 484 infection episodes, the top 3 infections were bacteremia 
(34.9%), pneumonia (19.6%), and surgical site infections (SSI) (7.2%). The site of 
infection was unknown in 29.8% of the patients. During the first month of the 
episode, Vancomycin, Teicoplanin, and Linezolid were prescribed in 72.9%, 16.9%, 
and 12.2% of patients, respectively. Compliance with the recommendations (drugs 
in A-I/A-II categories) of the latest Japanese MRSA treatment guidelines was fol-
lowed in 77.3%, 93.8%, and 89.7% of adult patients with bacteremia, pneumonia, 
and SSI, respectively. Blood culture tests were conducted in 54.7%, 37.0%, and 
27.6% of the adult episodes of bacteremia, pneumonia, and SSI. ConClusions: 
This is the first investigation to look at the actual status of MRSA infection using 
insurance claims data. It was found that the compliance with the Japanese MRSA 
treatment guidelines were generally high. However, utilization rate of blood culture 
test was low, even for the bacteremia patients. Further investigation is needed 
to determine the reason for this in order to ensure accurate diagnosis of MRSA 
infections in the future.
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objeCtives: Multidrug-resistant tuberculosis (MDR-TB) is designated an orphan 
disease in Germany, with less than 100 patients per year. TB case reporting has 
been obligatory since 2001 due to the Protection against Infection act (IfSG). The 
objective of this study was to compare the incidence of MDR-TB from different 
epidemiological data sources in Germany with data collected by the Robert-Koch-
Institute (RKI) according to the legal requirement. Methods: The following poten-
tial sources of epidemiological data of MDR-TB in Germany (for the year 2012) were 
searched: a systematic review of the literature, data from a statutory sickness fund 
(SHI) and data from the Federal Office of Administration (BVA) used for the risk 
adjustment scheme (Morbi-RSA) in the social health insurance system. Data from 
these sources were then compared with those collected by the RKI. Results: The 
systematic literature review provided 445 relevant abstracts which were screened 
by two independent reviewers. Selection of 16 possible full text papers revealed no 
relevant publications on MDR-TB in Germany. Data from sickness funds as well 
as the BVA also showed no reported cases of MDR-TB, although both gave indica-
tions on the incidence of drug-sensitive TB (91 cases/100,000 & 52 cases/100,000, 
respectively). The data provided by the RKI reported 4,187 cases of TB (incidence: 
5.2 cases/100,000) of which 65 cases (2.3%) were MDR-TB. ConClusions: Two 
factors are most striking: reports specific to MDR-TB are generally hard to find in 
SHI databases due to a lack of specific ICD-10 codes, but can be approximated with 
ICD-10 codes for drug-sensitive TB plus medication use. Furthermore, informa-
tion on TB incidence differs widely among the various data sources in Germany, 
possibly due to the different ways in which data are collected.
PIN4
the use of sINGle-arm evIDeNce IN the comParatIve effIcacy of 
INterferoN-free aNtIvIrals for treatmeNt-Naïve hePatItIs c 
GeNotyPe 1
Druyts E1, Kanters S2, Toor K1, Thorlund K2, Mills EJ3
1University of British Columbia, Vancouver, BC, Canada, 2Redwood Outcomes, Vancouver, BC, 
Canada, 3Stanford University, Stanford, CA, USA
objeCtives: Single-arm trials have played a major role in assessing the efficacy 
of interferon-free antiviral regimens for hepatitis C genotype 1. To facilitate evi-
dence synthesis, we have devised methods to integrate single-arm evidence into 
the network meta-analysis (NMA) framework to indirectly compare interferon-free 
and interferon-containing antiviral regimens. Methods: We conducted a system-
